Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial

Results expected by end of 2020JERUSALEM, Nov. 18, 2019 -- (Healthcare Sales & Marketing Network)-- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficac...Biopharmaceuticals
BiondVax Pharmaceuticals, influenza vaccine